Boehringer Ingelheim’s survodutide continued to draw scrutiny in obesity as Phase 3 updates were presented around tolerability, including discontinuation rates. ADA26 coverage pointed to patient pullouts tied to side effects as trial discussions intensify in a market dominated by weight-loss GLP-1s. Boehringer executives countered that tolerability remained consistent with the class, emphasizing targeted weight loss and body-composition readouts. The company highlighted MRI data on visceral fat reductions and framed lean mass loss as primarily limited in the trial. For investors and clinicians, the debate remains centered on the balance between efficacy depth and discontinuation dynamics, which can affect both labeling and uptake.